Cetuximab is a chimeric mouse-human monoclonal antibody to the human epidermal growth factor (EGF) receptor which is used in the treatment of metastatic colon and head and neck cancers. Cetuximab has been linked to mild and transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury.